<p>Oruka Therapeutics, Inc.（纳斯达克：ORKA - 获取免费报告）在周二的午盘交易中，股价创下 52 周新高，此前 HC Wainwright 将其目标价从 40.00 美元上调至 70.00 美元。HC Wainwright 目前对该股票给予买入评级。Oruka Therapeutics 的股价最高达到 65.64 美元，最后交易价格为 66.1010 美元，成交量为 417665 股。该股票此前收盘价为 61.38 美元。</p>
<p>获取 <strong>Oruka Therapeutics</strong> 的提醒：</p>
<p>ORKA 曾受到多份报告的关注。瑞银集团在 4 月 6 日的研究报告中将 Oruka Therapeutics 的目标价从 50.00 美元上调至 75.00 美元，并给予该公司 “买入” 评级。Leerink Partners 在 3 月 16 日的报告中将 Oruka Therapeutics 的目标价从 58.00 美元上调至 86.00 美元，并给予该股票 “跑赢大盘” 评级。Piper Sandler 在 12 月 18 日的报告中开始覆盖 Oruka Therapeutics，设定了 “增持” 评级和 75.00 美元的目标价。Guggenheim 在 3 月 13 日的报告中重申了 “买入” 评级，并设定了 60.00 美元的目标价。最后，Wedbush 在 3 月 13 日的报告中重申了 “跑赢大盘” 评级，并设定了 45.00 美元的目标价。十位投资分析师对该股票给予买入评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 74.90 美元。</p>
<p><strong>查看我们关于 Oruka Therapeutics 的最新报告</strong></p>
<h2>Oruka Therapeutics 的内部交易</h2>
<p>在其他 Oruka Therapeutics 的新闻中，内部人士 Joana Goncalves 在 3 月 16 日的交易中出售了 7641 股该公司的股票。该股票以平均价格 40.91 美元出售，总价值为 312,593.31 美元。交易完成后，内部人士持有该公司 33377 股股票，价值为 1,365,453.07 美元。这代表其持股比例减少了 18.63%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席执行官 Lawrence Otto Klein 在 3 月 16 日的交易中出售了 1729 股该公司的股票。该股票以平均价格 41.30 美元出售，总价值为 71,407.70 美元。交易完成后，首席执行官直接持有该公司 927,309 股股票，价值约为 38,297,861.70 美元。该交易使其持股比例减少了 0.19%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了价值 849,575 美元的 23765 股公司股票。内部人士持有该公司 24.69% 的股份。</p>
<h2>对 Oruka Therapeutics 的对冲基金看法</h2>
<p>一些对冲基金最近调整了对该公司的持股。加拿大皇家银行在第四季度将其在 Oruka Therapeutics 的持股增加了 47.2%。加拿大皇家银行目前拥有 1139 股该公司的股票，价值 34,000 美元，此前在该期间内购买了 365 股。Kennedy Capital Management LLC 在第四季度将其在 Oruka Therapeutics 的持股增加了 0.9%。Kennedy Capital Management LLC 目前拥有 48686 股该公司的股票，价值 1,476,000 美元，此前在该期间内购买了 420 股。Russell Investments Group Ltd.在第四季度将其在 Oruka Therapeutics 的持股增加了 35.0%。Russell Investments Group Ltd.目前拥有 3041 股该公司的股票，价值 92,000 美元，此前在该期间内购买了 788 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Oruka Therapeutics 的持股增加了 62.4%。Mirae Asset Global Investments Co. Ltd.目前拥有 2352 股该公司的股票，价值 71,000 美元，此前在该期间内购买了 904 股。最后，洛杉矶资本管理公司在第四季度收购了 Oruka Therapeutics 的新股份，价值约 37,000 美元。机构投资者和对冲基金持有该公司 56.44% 的股份。</p>
<h2>Oruka Therapeutics 股价上涨 7.5%</h2>
<p>该公司的市值为 32.7 亿美元，市盈率为-35.47，贝塔值为-0.54。该公司的 50 日移动平均价格为 40.07 美元，200 日移动平均价格为 32.63 美元。</p>
<p>Oruka Therapeutics（纳斯达克：ORKA - 获取免费报告）最近在 3 月 12 日发布了季度财报。该公司报告每股收益为（0.45 美元），超出市场共识预期的（0.61 美元）0.16 美元。平均而言，股票分析师预计 Oruka Therapeutics, Inc.在当前年度的每股收益为-3.41 美元。</p>
<h2>关于 Oruka Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Oruka Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于肿瘤学的新型肽类疗法。该公司的专有粘合肽平台旨在选择性地破坏驱动肿瘤生长和免疫逃逸的细胞内蛋白质 - 蛋白质相互作用。通过结合生物制剂的特异性与小分子的细胞渗透性，Oruka 旨在针对历史上被认为 “不可药物化” 的癌症通路。</p>
<p>该公司的主要候选药物 ONCT-01 目前正在进行针对晚期实体瘤患者的第一阶段临床试验，评估其安全性、耐受性和初步疗效。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Oruka Therapeutics 更具投资价值</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Oruka Therapeutics 吗？</h2>
<p>在你考虑投资 Oruka Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Oruka Therapeutics 并不在名单上。</p>
<p>虽然 Oruka Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ORKA

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

IBBQ

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

<p>Oruka Therapeutics (NASDAQ:ORKA) 的股票在 HC Wainwright 将其目标价从 $40 上调至 $70，并维持买入评级后，创下了 $66.10 的 52 周新高。瑞银和 Leerink Partners 也分别将目标价上调至 $75 和 $86。该股票经历了显著的内部人士抛售，内部人士持有 24.69% 的股份。机构投资者持有该公司 56.44% 的股份。Oruka 的市值为 32.7 亿美元，市盈率为 -35.47。该公司报告的季度每股收益为 -$0.45，超出预期</p>

<p>Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday after HC Wainwright raised their price target on the stock from $40.00 to $70.00. HC Wainwright currently has a buy rating on the stock. Oruka Therapeutics traded as high as $65.64 and last traded at $66.1010, with a volume of 417665 shares changing hands. The stock had previously closed at $61.38.</p>
<div class="lb-trans"><p>Oruka Therapeutics, Inc.（纳斯达克：ORKA - 获取免费报告）在周二的午盘交易中，股价创下 52 周新高，此前 HC Wainwright 将其目标价从 40.00 美元上调至 70.00 美元。HC Wainwright 目前对该股票给予买入评级。Oruka Therapeutics 的股价最高达到 65.64 美元，最后交易价格为 66.1010 美元，成交量为 417665 股。该股票此前收盘价为 61.38 美元。</p>
</div><p>Get <strong>Oruka Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Oruka Therapeutics</strong> 的提醒：</p>
</div><p>ORKA has been the subject of a number of other reports. UBS Group upped their target price on Oruka Therapeutics from $50.00 to $75.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, April 6th. Leerink Partners boosted their price target on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an &#34;outperform&#34; rating in a report on Monday, March 16th. Piper Sandler assumed coverage on Oruka Therapeutics in a report on Thursday, December 18th. They set an &#34;overweight&#34; rating and a $75.00 price target for the company. Guggenheim reissued a &#34;buy&#34; rating and set a $60.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Finally, Wedbush reissued an &#34;outperform&#34; rating and set a $45.00 price target on shares of Oruka Therapeutics in a report on Friday, March 13th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $74.90.</p>
<div class="lb-trans"><p>ORKA 曾受到多份报告的关注。瑞银集团在 4 月 6 日的研究报告中将 Oruka Therapeutics 的目标价从 50.00 美元上调至 75.00 美元，并给予该公司 “买入” 评级。Leerink Partners 在 3 月 16 日的报告中将 Oruka Therapeutics 的目标价从 58.00 美元上调至 86.00 美元，并给予该股票 “跑赢大盘” 评级。Piper Sandler 在 12 月 18 日的报告中开始覆盖 Oruka Therapeutics，设定了 “增持” 评级和 75.00 美元的目标价。Guggenheim 在 3 月 13 日的报告中重申了 “买入” 评级，并设定了 60.00 美元的目标价。最后，Wedbush 在 3 月 13 日的报告中重申了 “跑赢大盘” 评级，并设定了 45.00 美元的目标价。十位投资分析师对该股票给予买入评级，一位分析师给予卖出评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 74.90 美元。</p>
</div><p><strong>Check Out Our Latest Report on Oruka Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Oruka Therapeutics 的最新报告</strong></p>
</div><h2>Insider Transactions at Oruka Therapeutics</h2>
<div class="lb-trans"><h2>Oruka Therapeutics 的内部交易</h2>
</div><p>In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the transaction, the insider owned 33,377 shares of the company's stock, valued at $1,365,453.07. This represents a 18.63% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the completion of the transaction, the chief executive officer directly owned 927,309 shares of the company's stock, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 23,765 shares of company stock valued at $849,575. Insiders own 24.69% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Oruka Therapeutics 的新闻中，内部人士 Joana Goncalves 在 3 月 16 日的交易中出售了 7641 股该公司的股票。该股票以平均价格 40.91 美元出售，总价值为 312,593.31 美元。交易完成后，内部人士持有该公司 33377 股股票，价值为 1,365,453.07 美元。这代表其持股比例减少了 18.63%。该出售在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，首席执行官 Lawrence Otto Klein 在 3 月 16 日的交易中出售了 1729 股该公司的股票。该股票以平均价格 41.30 美元出售，总价值为 71,407.70 美元。交易完成后，首席执行官直接持有该公司 927,309 股股票，价值约为 38,297,861.70 美元。该交易使其持股比例减少了 0.19%。该出售的披露信息可在 SEC 文件中找到。在过去的九十天里，内部人士出售了价值 849,575 美元的 23765 股公司股票。内部人士持有该公司 24.69% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Oruka Therapeutics</h2>
<div class="lb-trans"><h2>对 Oruka Therapeutics 的对冲基金看法</h2>
</div><p>A number of hedge funds have recently modified their holdings of the business. Royal Bank of Canada lifted its holdings in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after purchasing an additional 365 shares during the period. Kennedy Capital Management LLC increased its stake in shares of Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock valued at $1,476,000 after buying an additional 420 shares during the period. Russell Investments Group Ltd. increased its stake in shares of Oruka Therapeutics by 35.0% in the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company's stock valued at $92,000 after buying an additional 788 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Oruka Therapeutics by 62.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company's stock valued at $71,000 after buying an additional 904 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 56.44% of the company's stock.</p>
<div class="lb-trans"><p>一些对冲基金最近调整了对该公司的持股。加拿大皇家银行在第四季度将其在 Oruka Therapeutics 的持股增加了 47.2%。加拿大皇家银行目前拥有 1139 股该公司的股票，价值 34,000 美元，此前在该期间内购买了 365 股。Kennedy Capital Management LLC 在第四季度将其在 Oruka Therapeutics 的持股增加了 0.9%。Kennedy Capital Management LLC 目前拥有 48686 股该公司的股票，价值 1,476,000 美元，此前在该期间内购买了 420 股。Russell Investments Group Ltd.在第四季度将其在 Oruka Therapeutics 的持股增加了 35.0%。Russell Investments Group Ltd.目前拥有 3041 股该公司的股票，价值 92,000 美元，此前在该期间内购买了 788 股。Mirae Asset Global Investments Co. Ltd.在第四季度将其在 Oruka Therapeutics 的持股增加了 62.4%。Mirae Asset Global Investments Co. Ltd.目前拥有 2352 股该公司的股票，价值 71,000 美元，此前在该期间内购买了 904 股。最后，洛杉矶资本管理公司在第四季度收购了 Oruka Therapeutics 的新股份，价值约 37,000 美元。机构投资者和对冲基金持有该公司 56.44% 的股份。</p>
</div><h2>Oruka Therapeutics Stock Up 7.5%</h2>
<div class="lb-trans"><h2>Oruka Therapeutics 股价上涨 7.5%</h2>
</div><p>The company has a market cap of $3.27 billion, a price-to-earnings ratio of -35.47 and a beta of -0.54. The firm has a 50 day moving average price of $40.07 and a two-hundred day moving average price of $32.63.</p>
<div class="lb-trans"><p>该公司的市值为 32.7 亿美元，市盈率为-35.47，贝塔值为-0.54。该公司的 50 日移动平均价格为 40.07 美元，200 日移动平均价格为 32.63 美元。</p>
</div><p>Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.16. On average, equities analysts expect that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.</p>
<div class="lb-trans"><p>Oruka Therapeutics（纳斯达克：ORKA - 获取免费报告）最近在 3 月 12 日发布了季度财报。该公司报告每股收益为（0.45 美元），超出市场共识预期的（0.61 美元）0.16 美元。平均而言，股票分析师预计 Oruka Therapeutics, Inc.在当前年度的每股收益为-3.41 美元。</p>
</div><h2>About Oruka Therapeutics</h2>
<div class="lb-trans"><h2>关于 Oruka Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”</p>
<div class="lb-trans"><p>Oruka Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于肿瘤学的新型肽类疗法。该公司的专有粘合肽平台旨在选择性地破坏驱动肿瘤生长和免疫逃逸的细胞内蛋白质 - 蛋白质相互作用。通过结合生物制剂的特异性与小分子的细胞渗透性，Oruka 旨在针对历史上被认为 “不可药物化” 的癌症通路。</p>
</div><p>The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.</p>
<div class="lb-trans"><p>该公司的主要候选药物 ONCT-01 目前正在进行针对晚期实体瘤患者的第一阶段临床试验，评估其安全性、耐受性和初步疗效。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Oruka Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Oruka Therapeutics 更具投资价值</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oruka Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Oruka Therapeutics 吗？</h2>
</div><p>Before you consider Oruka Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Oruka Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Oruka Therapeutics 并不在名单上。</p>
</div><p>While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Oruka Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year High on Analyst Upgrade

Market Beat

Oruka Therapeutics

Invesco Nasdaq Biotechnology ETF

Oruka Therapeutics（NASDAQ:ORKA）因分析师上调评级而创下 1 年新高